Enphys Acquisition Corp. (NYSE:NFYS) announced this afternoon that it has signed a non-binding letter of intent (LOI) to combine with a leading and well-established advanced biofuels company in Latin America for undisclosed terms.
Enphys is led by CEO Jorge de Pablo, Chairman Carlos Guimarães, CFO Pär Lindström, and COO Matias de Buján.
At the SPAC of Dawn The SPAC world is set to get its newest member later today when Launch Two (NASDAQ:LPBBU) begins trading having priced its $200 million IPO overnight. The technology SPAC is the first to IPO this quarter and comes after the newfound SPAC issuance momentum appeared to throttle down slightly in September,...
Launch Two Acquisition Corp. announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “LPBBU”, Tuesday, October 8, 2024. The new SPAC’s primary search focus will be on technology and software infrastructure companies whose products and services target financial services, real estate and...
Oaktree III Life Sciences (NASDAQ:OACCU) has filed for a $175 million SPAC with some of the most aggressively team-friendly terms seen so far in the second half of 2024. The new SPAC’s units contain 1/5 warrants and the trust is not set to be overfunded. Only the warrantless Cantor Equity Partners (NASDAQ:CEP) has IPO’d so...
At the SPAC of Dawn SPACs are set to have a sleepy start to their post-Rosh Hashanah week with no votes on the docket until Wednesday. Three SPACs are to hold extension votes that day and Clover Leaf (OTC:CLOE) will try again to close its combination with Kustom Entertainment after several adjournments on Friday. In...
Terms Tracker for the Week Ending October 4, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week was much, much heavier on the S-1 filings. There were five new SPACs filed along with six amended S-1 registration statements making good...